Podcast: Irresistible cancer therapies w/Nick Goldner
Check out this episode of Translation by our partners at 50 years about how our Founders, Nick Goldner and Chris Bulow, went from getting PhDs studying antibiotic resistance to starting a company whose sole mission is to develop novel
Full ArticleTargeted Drug Discovery Summit- Feb. 2022.
Founder and CEO of resistanceBio, Nick Goldner, will speak at this year’s Targeted Drug Discover Summit. The summit will take place in Boston, MA, from February 22nd to 24th. Please click on the link below for Summit details!
Full ArticleR-Bio is proud to be partnering with 50 Years!
“What doesn’t kill you makes you stronger” is not just a cute saying for a throw pillow or gym shirt — it’s an actual biological phenomenon.
Full ArticleCheck out our interview in FierceBiotech.com!
Could a single pill treat a tumor today and head off its drug resistance mechanisms tomorrow? resistanceBio is on the case. Cancer drugs stop working when malignant cells develop molecular changes that allow them to evade the drugs’ effects.
Full ArticleSubclonal cooperation drives metastasis
Most human tumours are heterogeneous, composed of cellular clones with different properties present at variable frequencies. Highly heterogeneous tumours have poor clinical outcomes, yet the underlying mechanism remains poorly understood.
Full ArticleFiboblasts and electinib: The evolutionary games
Could a single pill treat a tumor today and head off its drug resistance mechanisms tomorrow? resistanceBio is on the case.
Full ArticleCollateral sensitivity networks reveal instability
Drug resistance remains an elusive problem in cancer therapy, particularly for novel targeted therapies.
Full ArticleBig Bang model of colorectal tumor growth
A Big Bang model of human colorectal tumor growth. What happens in the early, still undetectable human malignancy is unknown because direct observations are impractical.
Full Article